Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
Total Valuation
Radiopharm Theranostics Limited Sponsored ADR has a market cap or net worth of $52.37M. The enterprise value is $19.79M.
Market Cap$52.37M
Enterprise Value$19.79M
Share Statistics
Radiopharm Theranostics Limited Sponsored ADR has 11,814,054 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,814,054
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Radiopharm Theranostics Limited Sponsored ADR’s return on equity (ROE) is -0.86 and return on invested capital (ROIC) is -53.35%.
Return on Equity (ROE)-0.86
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-53.35%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee259.53K
Profits Per Employee0.00
Employee Count14
Asset Turnover0.04
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Radiopharm Theranostics Limited Sponsored ADR is ―. Radiopharm Theranostics Limited Sponsored ADR’s PEG ratio is 0.01.
PE Ratio―
PS Ratio13.46
PB Ratio1.09
Price to Fair Value1.09
Price to FCF-1.33
Price to Operating Cash Flow―
PEG Ratio0.01
Income Statement
In the last 12 months, Radiopharm Theranostics Limited Sponsored ADR had revenue of 3.63M and earned -38.34M in profits. Earnings per share was -5.28.
Revenue3.63M
Gross Profit39.28K
Operating Income-38.17M
Pretax Income-38.24M
Net Income-38.34M
EBITDA-38.17M
Earnings Per Share (EPS)-5.28
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Radiopharm Theranostics Limited Sponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.23
52-Week Price Change2.28%
50-Day Moving Average4.79
200-Day Moving Average5.14
Relative Strength Index (RSI)46.14
Average Volume (3m)284.14K
Important Dates
Radiopharm Theranostics Limited Sponsored ADR upcoming earnings date is Sep 24, 2026, TBA (Not Confirmed).
Last Earnings DateFeb 27, 2026
Next Earnings DateSep 24, 2026
Ex-Dividend Date―
Financial Position
Radiopharm Theranostics Limited Sponsored ADR as a current ratio of 2.67, with Debt / Equity ratio of ―
Current Ratio2.67
Quick Ratio2.67
Debt to Market Cap0.00
Net Debt to EBITDA0.76
Interest Coverage Ratio-584.59
Taxes
In the past 12 months, Radiopharm Theranostics Limited Sponsored ADR has paid 103.29K in taxes.
Income Tax103.29K
Effective Tax Rate>-0.01
Enterprise Valuation
Radiopharm Theranostics Limited Sponsored ADR EV to EBITDA ratio is -0.52, with an EV/FCF ratio of -0.54.
EV to Sales5.45
EV to EBITDA-0.52
EV to Free Cash Flow-0.54
EV to Operating Cash Flow-0.54
Balance Sheet
Radiopharm Theranostics Limited Sponsored ADR has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share-$0.53
Margins
Gross margin is ―, with operating margin of -1050.63%, and net profit margin of -1055.27%.
Gross Margin―
Operating Margin-1050.63%
Pretax Margin-1052.43%
Net Profit Margin-1055.27%
EBITDA Margin-1050.43%
EBIT Margin-1050.63%
Analyst Forecast
The average price target for Radiopharm Theranostics Limited Sponsored ADR is $22.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$22.50
Price Target Upside402.23% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―